Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.

Abstract

OBJECTIVE:

To assess the efficacy of deferasirox as an iron chelator, with specific reference to reducing cardiac iron overload.

DESIGN:

Prospective, open label, single arm study between 2008-2010. SETUP: Thalassemia center at a teaching hospital.

PARTICIPANTS:

30 multitransfused Thalassemia Major (TM) patients receiving deferasirox (DFX) therapy.

METHODS:

All patients had MRI T2*evaluation for cardiac iron load before starting DFX therapy. MRI T2* was performed on a 1.5 tesla Siemens sonata machine using thalassemia tools software and the ejection fraction measured using standard cardiac magnetic resonance sequence. Quantification of cardiac iron deposit was categorized into T2* <10 ms as high cardiac risk, 10-20 ms as intermediate risk, and >20 ms as low risk. We also estimated left ventricular ejection fraction (LVEF), end systolic volume (ESV) and end diastolic volume (EDV) using standard sequence. EF <56 % was considered to be significant cardiac dysfunction. DFX was administered in an initial dose of 20mg/kg/day and increased to a maximum of 35mg/kg/day. Serum ferritin level was estimated in pretransfusion samples at 1-3 monthly intervals. The primary end point of the study was change in serum ferritin level and cardiac MRI T2* value after 12-18 months therapy.

RESULTS:

Of the 30 patients, cardiac iron value of >20 ms was seen in 15 (50%), whereas 9 (30%; ) had 20-10 ms, and 6 (20%) had <10 ms. The mean serum ferritin pre DFX therapy of all cases was 3859.8 ± 1690.70 ng/mL (1066 - 6725 ng/mL) and mean cardiac T2* was 23.8 ± 15.2 ms (6.24-69.2 ms). After 12 to 18 months of DFX therapy on a mean dose of 33 mg/kg/day, the mean serum ferritin was 2693.4 ± 1831.5 ng/mL (drop by 30.2%, P<0.001) and mean cardiac T2* was 24.2 ± 12.9 ms (increase of 1.6 %, P=0.87). Percentage change in cardiac iron was greater in high risk (24.8%) and intermediate risk (33.4%) patients than low risk patients (8.4%), though these values were not statistically significant. LVEF was 62.0 (± 7.0%) before treatment and changed to 58.9 (± 4.8%) after 18 months of therapy but the values remained within normal range and this change was not significant (P=0.061). Adverse effect of DFX included diarrhea, maculopapular skin rash and transient proteinuria that necessitated temporary stoppage of medication.

CONCLUSION:

Deferasirox monotherapy has a good safety profile and effectively chelates total body iron. It is also a good myocardial iron chelator, more efficacious in moderate to severe cardiac iron overloaded patients.

• Authors: Rashid Merchant, Javed Ahmed, Pradeep Krishnan, Bhavin Jankharia
• Journal: Indian pediatrics (Indian Pediatr) Vol. 49 Issue 4 Pg. 281-5 (Apr 2012) ISSN: 0974-7559 [Electronic] India
• PMID: 21992861 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Benzoates
• Iron Chelating Agents
• Triazoles
• Ferritins
• Deferasirox

Topics

• Adolescent
• Benzoates (adverse effects, therapeutic use)
• Child
• Deferasirox
• Female
• Ferritins (blood, metabolism)
• Humans
• Iron Chelating Agents (adverse effects, therapeutic use)
• Iron Overload (drug therapy)
• Magnetic Resonance Imaging
• Male
• Myocardium (metabolism)
• Prospective Studies
• Thalassemia (drug therapy)
• Triazoles (adverse effects, therapeutic use)
• Young Adult